National Tumor Brain News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A vaccine to slow the progression of the deadliest form of brain cancer has shown promise in early clinical trials by extending the average survival time from 15 to 26 months.

New yorkUnited statesJohn wishmanHonggang cuiTracey kassmanRoswell park comprehensive cancer centerNational tumor brain societyJohns hopkins whiting school of engineeringNational tumor brainNew york based mimivaxJohns hopkins whiting school